Cambridge Investment Research Advisors, Inc. Citius Pharmaceuticals, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Jul 13, 2022	SELL	$0.88 - $1.87 $252 - $536	-287 Reduced 0.52%	54,600 $50,000
Q4 2021 Feb 03, 2022	BUY	$1.51 - $2.2 $82,879 - $120,751	54,887 New	54,887 $84,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

23.7M

Call Options Held

83.1K

Put Options Held

32.1K

Armistice Capital, LLC New York, NY

7.28M
Shares

$18.7 Million
0.06% of portfolio
Vanguard Group Inc Valley Forge, PA

6.44M
Shares

$16.6 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.88M
Shares

$4.83 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.81M
Shares

$4.64 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.16M
Shares

$2.98 Million
0.0% of portfolio

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $376M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account